Story perspectives

Orforglipron: Promising Weight-Loss Pill Nears FDA Approval

8/30/2025

Summary

Story summary

Eli Lilly's weight-loss pill, orforglipron, has successfully completed Phase 3 trials and is close to FDA approval.
This daily pill offers a more convenient alternative to existing injectable treatments.
Insurance coverage for orforglipron is uncertain, potentially leading to out-of-pocket expenses for patients.
Other weight management options include structured programs like WeightWatchers and Noom.
If approved, orforglipron could greatly influence the weight-loss market, though lifestyle changes remain crucial.

1 of 1

Story summary

Eli Lilly's weight-loss pill, orforglipron, has successfully completed Phase 3 trials and is close to FDA approval.
This daily pill offers a more convenient alternative to existing injectable treatments.
Insurance coverage for orforglipron is uncertain, potentially leading to out-of-pocket expenses for patients.
Other weight management options include structured programs like WeightWatchers and Noom.
If approved, orforglipron could greatly influence the weight-loss market, though lifestyle changes remain crucial.